A Look at the Role of VEGF and EGFR
Inhibitors in Colorectal Cancer
A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.


This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Lilly USA, LLC

Description:
Colorectal cancer, when discovered early, is highly treatable. However, when the disease has spread, or metastasized, treatment and management becomes much more difficult. Metastatic colorectal cancer (mCRC) carries a poor prognosis, with a 5-year survival rate of approximately 70% for regional metastases and 13% for distant metastases. The prognosis of patients with mCRC has significantly improved in recent years with the introduction of inhibitors of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Treatment selection is based largely on the stage (extent) of the cancer and many patients undergo surgery as a first treatment although it is unlikely to cure the disease. Several targeted agents that show improved efficacy and safety in mCRC are now approved, both alone and in combination.

Upon Completion of this activity, participants will be able to:

  • Analyze the rationale and role of VEGF- and EGFR-targeted agents in the treatment of mCRC

  • Examine the role and use of molecular testing to guide treatment selection for patients with mCRC

  • Assess the safety, efficacy and when it is appropriate to incorporate current targeted therapies into the treatment paradigm for mCRC

  • Individualize management based on factors that affect outcomes including tumor characteristics, treatment history, common adverse effects, and age for optimal care

  • Discuss strategies to mitigate side effects related to treatment with VEGF- and EGFR-targeted agents in patients with mCRC
     

Faculty: Cathy Eng, MD, FACP
Associate Medical Director, Colorectal Center
Director of Network Clinical Research, GI Medical Oncology
MD Anderson Cancer Center
Department of Gastrointestinal Medical Oncology

Disclosure:

Dr. Eng serves as a consultant to Bayer and Sirtex; receives research support from Daiichi and Keryx; is on the speaker's bureau for Genentech. Her presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This activity is supported by an educational grant from
Lilly USA, LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue